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ABSTRACT
Cancer emerges from an uncontrollable division of the organism’s cells, creating a tumour.
These tumours can emerge from any part of the human body. The increase of cellular divi-
sion and growth can be created by mutations in the genome. Several methodologies are ap-
proached, in the research, to finding new cancer genes. The insertional mutagenesis (IM)
has been one of the most used, in which the mouse is infected by a retrovirus or a transpo-
son, increasing the gene expression in the insertions’ vicinity.
The data used in work essay are a collection of independent studies of IM in mice. After
its processing, the data has 3,414 samples, having information of 7,751 genes. Each sam-
ple matches a type of cancer (colorectal, hematopoietic, hepatocellular carcinoma, lym-
phoma, malignant peripheral nerve sheath, medulloblastoma and pancreatic).
The main goal of this project is to determine if there are specific genes for a particular
type of cancer. And, if there are, which are the 15 most evolved genes for that type of cancer.
Machine learning (ML) is a subject where its goal is to increase knowledge based on
given experimental data, allowing it to execute predictions and accurate decisions. To an-
swer our purpose, it is necessary the transform the data into a dissimilarity relation be-
tween samples. Different approaches were used: two of them are known from the litera-
ture (Hamming distance and Jaccard distance) and two new metrics were developed (Gene
Dependent Method (GDM) and Gene Independent Method (GIM)). With these transforma-
tions, unsupervised learning methods (such as Principal Component Analysis (PCA) and
t-distributed stochastic neighbor embedding (t-SNE)) and supervised learning approach,
testing different classifiers by crossed validation, were used.
The main results show that some genes may be specific to a particular type of cancer.
Therefore, it is possible to create a ranking gene, according to its importance to a type of
cancer. 105 genes are presented (15 genes of each type of cancer), of which 18 were not
annotated yet and 19 have already been mentioned in the literature to be involved in the
development of the selected cancer tissue. Afterwards it must be performed a proper in
vitro and in vivo validation.
Keywords: Cancer; cancer genes; insertional mutagenesis; machine learning.
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RESUMO
O cancro surge da divisão incontrolável de células de um organismo, criando um tumor.
Estes tumores podem surgir em qualquer parte do corpo do ser vivo. O aumento da divisão
e crescimento celular pode dever-se a mutações no genoma. São várias as metodologias
abordadas na investigação para a descoberta de novos genes de cancro. A mutação por
inserção (IM) tem sido uma abordagem bastante utilizada, no qual o rato é infetado por
um retrovírus ou um transposão, aumentando a expressão do gene que se encontra na
vizinhança da inserção.
Os dados usados neste trabalho correspondem a uma coleção de estudos indepen-
dentes de IM em ratos. Após o seu processamento, os dados contêm 3,414 amostras, tendo
informação de 7,751 genes. Cada uma das amostras corresponde a um tipo de cancro (colo-
rectal, tecido hematopoiético, carcinoma hepatocelular, linfoma, tumor maligno de bainha
nervosa, meduloblastoma e pâncreas).
O objetivo principal deste projeto é determinar se existem genes específicos para um
determinado tipo de cancro e, se sim, quais são os 15 genes mais envolvidos para o desen-
volvimento do mesmo.
A aprendizagem de máquina (ML) tem como objetivo ganhar conhecimento com base
em dados experimentais fornecidos, permitindo que este possa realizar previsões e de-
cisões precisas. Para se responder ao objetivo, é necessária a transformação dos dados
numa relação de dissimilaridade entre amostras. Foram usadas quatro abordagens: duas
delas são descritas na literatura (a distância de Hamming e a distância de Jaccard) e duas
novas métricas foram desenvolvidas (o método de gene dependente (GDM) e o método
de gene independente (GIM)). A partir destas transformações foram usadas metodologias
de aprendizagem não supervisionada (a Análise de Componentes Principais (PCA) e o t-
distributed stochastic neighbor embedding (t-SNE)), e a metodologia supervisionada, tes-
tando diferentes classificadores por validação cruzada.
Os resultados principais mostram que existem genes que poderão ser específicos para
um dado tipo de cancro. Assim sendo, é possível criar uma ordenação dos genes de acordo
com a sua importância face a um tipo de cancro. São apresentados 105 genes (15 genes para
cada tipo de cancro), dos quais 18 ainda não foram anotados e 19 já foram mencionados
na literatura por estarem envolvidos no desenvolvimento do cancro do tecido selecionado.
Posteriormente deverá ser realizada a devida validação in vitro e in vivo.
Palavras-chave: Aprendizagem de máquina; cancro; genes de cancro; mutagénese por in-
serção.
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INTRODUCTION
1.1. MOTIVATION
Cancer is the name given to an assembly of more than 100 diseases1. All these diseases
can be very distinctive of each other. Nonetheless, they all have a similar starting point: an
abnormal cell division, creating more cells than the body needs, producing a tumour.
Every year the number of new cases of cancer increases. In 2008, 12.7 million new reg-
istrations and 7.6 million deaths as a possible result of this disease were estimated [1]. A
recent study, analysing data from 2012, estimates a registration of 14.1 million new cases of
cancer and 8.2 million deaths as a possible result of this disease [2]. This growth is caused
essentially as a result of the populations’ rise, as well as to the exposition to risk factors.
Cancer is caused by changing the genetic information - the deoxyribonucleic acid (DNA)-
of a cell. This alteration is called mutation and most of the time cells can repair it.
Cancer research is extremely important due the impact it can cause on our society.
Analysing the changes of a gene or pathways, it is possible to predict which patients are
likely to have a better or worse diagnosis.
1.2. OBJECTIVES
The key focus of this project is to improve understanding of biological processes that lead
to cancer. The data collected contains information of exogenous DNA which integrates the
mouse’s genome - insertional mutagenesis (IM). This integration will activate genes in its
vicinity, in special, cancer genes.
1http://www.cancer.gov/about-cancer/what-is-cancer, accessed: July 2015
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The main biological question of the project is to determine which genes are likely to
be a candidate as cancer genes to a specific type of cancer. To answer this question, the
strategy is to use Machine Learning (ML).
Machine learning uses algorithms that can learn from data [3]. Classification methods
allow to make predictions and decisions. For example, classification techniques have been
used to extract cancer genes from large gene expression datasets [4–6]. IM screening data
are represented by a very sparse Boolean matrix, and as such is very different from gene
expression data. For this reason, the first problem is to know which classifier is suitable
for application to sparse Boolean data. Several classifiers will be tested. To capture this
in the classifier, the data will be transformed in a distance matrix. This evaluation will be
performed using two classes, representing two distinct cancer types. To conclude, it will be
evaluated feature selection methods to determine which genes interact in specific types of
cancer.
1.3. STRUCTURE OF THE DISSERTATION
This dissertation is divided into seven chapters. In this first chapter, a brief introduction of
the motivation and the main aims of the work are provided.
Second chapter - Cancer research
Introduces several aspects related to cancer, as well as the research done to find new
cancer genes.
Third chapter - Machine Learning
Presents an explanation of several important aspects of learning algorithms and their
evaluation. To understand differences in the data it is explained some approaches
to transform it. It is also discusses an approach to find important features from a
dataset.
Fourth chapter - Data
Describes how the data was generated, how it was organized and explains the pre-
processing performed, to have the final dataset.
Fifth chapter - Methodology
Explains the several steps of the work developed: the approaches used to transform
the data; the unsupervised and supervised learning methods; as well as the ranking
method.
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Sixth chapter - Results and discussion
Addresses the main results of this work: the visualization of the unsupervised learn-
ing methods; the performances of selected classifiers used in supervised learning
methods; and a list of potential genes that are involved in tumourigenesis.
Seventh chapter - Conclusion
Describes the main conclusions of the work, the limitations and recommendations
for future work.

2
CANCER RESEARCH
2.1. CANCER
Cancer is the name given to a group of diseases. All the different types of cancer arise
with an unexpected aberrant cell division - neoplasia -, which disseminate to near tis-
sues - metastesis. The Human body contains approximately 37 trillion and 200 million
(3.72×1013) cells and all of them can originate a tumour [7]. Not all tumours lead to can-
cer. In fact, tumours can be distinguished in two groups: benign and malignant. The first
one does not have the ability to invade other tissues, which makes the removal a simple
process. The second can spread to neighbour tissues. Even if the tumour is cut out, the
organism still carries some cancer cells, which later can develop a new tumour.
Cancer is a genetic disorder. It is caused by changing gene expression, which controls
the cell function. These changes can generate mutations. The probability of having a spo-
radic mutation in each base pair (bp) is estimated to be 1 in 100 million (1.1×10−8)[8]. This
value may seem low, but due the enormous quantity of bp that the Human genome con-
tains, as well as, the massive number of cells each individual has in their lifetime and their
risk behaviours, the probability increases largely. In addition, there are many agents which
change DNA. They can be caused naturally by environmental factors due to physical (e.g.
radiation), chemical (e.g. smoke) and biological (e.g. virus) causes, as well as, by genetic
alterations (sporadic or hereditary) [9, 10].
Mutations happen all the time in our cells. In fact, during the cell cycle, cells have mech-
anisms which can detect an error and repair them. If the cell cannot replace its damages, it
will receive a signal to initiate the process to its death -apoptosis [11].
5
6 2. CANCER RESEARCH
Not all cancer cells are generated by mutations. Epigenetics is the study of cellular and
physiological alteration caused by exogenous factors. In this situation, the alterations do
not change the nucleotide sequence. Epigenetics alterations can change the expression of
a gene, increasing or decreasing it.
2.1.1. THE CANCER CELL EVOLUTION
The cell - the basic structural, functional and biological unit of organisms – preserves, in-
side it, one of the most important discovery in biological science, the DNA. This molecule
contains the information that the cell needs. This information is stored in genes. One of
the functions of the cell is to reproduce itself, dividing itself in two daughter cells and trans-
mit its genetic information - cell cycle. It is estimated that this mechanism repeats between
50-70 billion cells per day in our organism to replace dead cells [12]. This process has two
steps: interphase - the cell growth, accumulating compounds and duplicating its DNA; and
mitosis - the cell splits itself into two distinct cells. These two phases have checkpoints,
which ensures the appropriate replication of the DNA and division of the cell [13].
Before the transition from a normal to a cancer cell -tumourigenesis - can happen, the
cell must overcome all its protections. It can be considered as an accelerated version of
Darwin’s evolution theory: the individual receives an inherited genetic variation, it gets
selective advantages and transmits it to its next generation [14–16]. In fact, if genes have
different activities than usual, it will change, therefore, the cell’s activity and induce the ac-
cumulation of several alterations in its DNA along its generations (during years or decades).
They will overcome all checkpoints and gain some selective advantages compared to the
normal cells [17]. With this accumulation, the cell will change its properties, and then, can
evolve to a cancer phenotype [18].
To be considered as a cancer cell, the cell has to have several characteristics. Hanahan
and Weinberg [19, 20] suggest that cancer cells can be summarised in 10 hallmarks (Fig-
ure 2.1):
Six basic hallmarks, representing the fundamental basis of malignancy:
Sustaining proliferative signalling
Normal cells regulate carefully the process of growth signals, insuring the cell home-
ostasis. However, cancer cells can overcome this mechanism, for example, produc-
ing more growth factor, increasing the number of receptors on the cell surface and
changing the signalling pathways.
Evading growth suppressors
Normal cells rely on anti-growth signals to regulate their growth. Most of these pro-
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cesses depend on the actions of tumour suppressor genes. Cancer cells become in-
sensitive to mechanisms that regulate negatively the cell proliferation.
Resisting cell death
Due the DNA damage and other cellular stresses, normal cells may initiate apoptosis
[11]. Most of cancer cells are less sensitive to similar stresses, avoiding apoptosis and
contributing to the uncontrollable division.
Enabling replicative immortality
The number of division a cell can do is limited. These limits are usually established
by telomeres (the ends of chromosomes). Along each cell division, in normal cells,
telomeres get shorter until they are not able to divide. In contrast, in cancer cells,
telomeres are preserved, allowing the cell to divide an unlimited number of times.
Inducing angiogenesis
Angiogenesis is the process of creating new blood vessels, mediated mainly through
vascular endothelial growth factor. It plays a critical role in tumour growth, supplying
the cancer cells with oxygen and nutrients.
Activating invasion and metastasis
Metastasis is the cause of 90% of deaths from solid tumours [21]. Here, cancer cells
may escape from the primary site and disseminate into distant organs. This process
is not well understood, but it is known to involve a large number of secreted factors
which breaks the tissue, allowing the invasion into blood vessels, and then, creating
a new tumour in another place in the organism.
The acquisition of these hallmarks of cancer is made possible by two enabling charac-
teristics:
Genome instability and mutation
Cancer cells achieve genome instability by increasing their mutation’s rate. They
increase their sensitivity to mutagenic agents or breakdown of DNA repair macha-
nisms.
Tumour promoting inflammation
Immune cells might infiltrate tumours and produce inflammatory responses. Inflam-
mation can release chemicals into the tumour microenvironment, leading to genetic
mutations and helping tumours acquire the hallmarks of cancer
Furthermore, two emerging hallmarks might be involved in the development of cancer:
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Figure 2.1: Hallmarks of cancer.
Characteristics the normal cell has to collect to achieve the cancerous phenotype.
Figure adapted from Hanahan and Weinberg (2011) [20].
Deregulating cellular energetics
The uncontrolled growth and division of cancer cells may rely on the reprogramming
of cellular metabolism, including increased aerobic glycolysis (known as the Warburg
effect).
Avoiding immune destruction
The immune system is responsible for protecting the organism, including recogni-
tion and elimination of cancer cells. Evasion of this immune surveillance by weakly
immunogenic cancer cells is an important emerging hallmark of cancer.
2.1.2. THE CANCER GENES
It is widely accepted that tumourigenesis is a process which arises as a result of different
activity of the genes present in the cell and they can differ between different types of can-
cers. The main challenge that researchers face is understanding which genes must be active
or inactive to stop the normal operation of the cell and arouses to cancer. Some of their
names are known [22]. However, it is believed that most of them are still a mystery. The
term "cancer gene" will be used throughout this dissertation to describe a gene for which
mutations have been causally implicated in cancer. Cancer genes are commonly classified
in two groups:
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Proto-oncogenes
Proto-oncogenes (e.g. myc and ras) are genes that incentives the cell growth. They
turn to oncogene when they are mutated, being more active, allowing cells to grow
more and surviving when they should not. Usually the overexpression of these genes
is caused by gene amplification or chromosomal translocation [23].
Tumour suppressor genes
Tumour suppressor genes (e.g. p53) have as main purpose the reduction of cell pro-
liferation. When these genes do not work correctly, the cell is able to grow out of
control. This happens due to the mutation, causing loss of function of the gene.
It is important to understand that tumourigenesis develops as a result of activation of
proto-oncogene, becoming an oncogene, and the inactivation of tumour suppressor genes.
In general, to the tumour suppressor gene loss its function, it must be mutated in both
alleles (recessive mutation)[24]. In contrast, since the mutation in oncogenes corresponds
to the gain-of-function, most of its mutations involve only an individual allele (dominant
mutations)[25].
2.2. THE RESEARCH
Cancer formation results from gene mutations, which regulates the cell’s growth. Major tu-
mours result either gain or loss-of-function of gene’s activity. Discovering which genes are
involved in tumourigenesis allows, for example, the creation of drugs that can act against
this abnormal gene or the protein encoded.
2.2.1. DISCOVERING GENES AND PATHWAYS INVOLVED IN CANCER
In order to find new genes which leads to cancer’s hallmarks, several strategies are used.
Most of them are tested in humans and in mouse [26]. Some techniques use tumour tissues
from patients. On the other hand, a large part of the research uses animal models. The
mouse is the biological model most used in research. It has a fast reproduction rate, a short
life cycle and a small size, so it can be preserved in smaller spaces. In addition, the mouse
is also physically and genetically similar to humans. Most genetics finding in mouse have a
homology in human[27].
From all methods to discover new candidates to cancer genes, insertional mutagenesis
(IM) has been a very efficient tool. The following work uses this approach in mouse and it
is described below.
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2.2.2. INSERTIONAL MUTAGENESIS
Insertional mutagenesis (IM) is a mechanism by which an exogenous DNA element inte-
grates the genome of a host cell. It can be used in several fields of molecular biology, such
as, gene therapy [28], gene regulation[29] and oncogene discovery [26]. As mentioned be-
fore, the mouse is the most used model for cancer study, although IM has also been per-
formed several different organisms, such as other vertebrates (e.g. chicken [30], zebrafish
[31]), insects (e.g. Drosophila melanogaster [32]), plants (e.g. Arabidopsis thaliana [29] and
rice [33]) and fungus [34].
HOW IT WORKS
In this technique, the mouse is infected by a retrovirus or a transposon. They will infect
the healthy cells and integrates their genome in the host cells. By consequence, this inte-
gration will deregulate genes in the vicinity, even in large distances [35], and can cause a
perturbation of the phenotype. When the incorporation increases the expression of proto-
oncogenes or decreases of tumour suppressor genes, it can result in an accelerated cell
proliferation. The integration can alter the gene expression in different ways: either up-
or downstream, changing its expression level and rarely the encoded protein; or within
the gene, resulting in a different encoded protein or in its inactivation [36]. Regions in
the genome that contain constantly insertions located in the same loci, in independent tu-
mours, are referred as common insertion site (CIS). CIS show a significant overlap with
human cancer genes (Figure 2.2)[37].
MECHANISM OF INSERTIONAL MUTAGENESIS
In order to find new cancer genes, two main mechanisms have been used : retrovirus and
transposons. Retrovirus (e.g. murine leukemia virus (MuLV) and mouse mammary tumour
virus (MMTV)) is a virus which its genome has a form of ribonucleic acid (RNA)and has the
ability to convert its sequence into DNA by reverse transcription. Transposon (e.g. sleeping
beauty and piggybac) is a DNA sequence that changes its position within the genome.
It is not known why this integration happens in the vicinity of a cancer gene. However,
these mechanisms have integration biases [38].
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Figure 2.2: Outline for the cancer gene discovery using insertional mutagenesis (IM).
A- The mouse is infected with a retrovirus or transposon (1). After create a tumour (2), DNA is extracted (3),
amplified -by polymerase chain reaction (PCR)- (4), sequenced and mapped (5). In order to find clusters
of insertions some statistical and bioinformatics analysis is performed, also knows as CIS(6). Genes in the
vinicity of CIS are potential cancer genes (7). B- After find new candidates to be a cancer genes, they must be
validated. This validation consists in verify if the gene transform normal cells in cancer cells. It can be tested
in vitro (1) and/or in vivo(2). If the transformation happens, a cross-species to find the orthologues and
homologs genes in human is performed (3). The final step is create a drug which can correct the abnormal
gene expression (4).

3
MACHINE LEARNING
3.1. LEARN FROM EXAMPLES
Machine Learning (ML) is a branch of computer science emerged from the study of arti-
ficial intelligence, pattern recognition and computational learning theory. This discipline
is deployed in several fields, such as bioinformatics (e.g. evolution, systems biology, ge-
nomics and others [39]), medical diagnosis [40], computer vision (e.g. image recognition
[41]), speech recognition [42], document classification (e.g. spam [43]), music [44], games
(e.g. checkers [45]) and others.
The main goal of ML is to extract knowledge from experimental data, allowing the com-
puter to make accurate predictions and decisions.
All ML problems start with a dataset, a collection of information. This information,
also called experiences or instances, are individual and independent examples given to the
learner, representing observations. Each experience is characterized by its values, repre-
senting a set of features. A feature (also known as attribute) is a measurement of something
and can be nominal and numeric. Usually the dataset is defined as a matrix where the
rows (m) are the instances collected, and the columns (n) are the features, representing the
dimensionality of the data.
ML methods can be subdivided into two main groups based on the type of problem
they can solve:
Supervised learning The learner gets a set of instances with their respective label, D(X ,Y ),
where D is the dataset, X is the set of vectors and Y the label. This method can be
divided into two groups: classification and regression. The main difference between
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these two analyses is the output type. In classification, the result is a discrete value,
representing a class. In regression, the output is a continuous value and it depends
on the independent variable given.
Unsupervised learning The learner gets a set of instances without labels, not being able
to evaluate the method’s error. The approaches used are essentially clustering and
dimensionality reduction. The major difference between them is the way the reduc-
tion is done before their performance. In clustering, the number of experiences is
reduced to generalize them. In dimensionality reduction, it is cutback the number
of features, transforming them and reducing the dimensionality (preferably in two
dimensions (2D) or three dimensions (3D)) to be easier to visualize.
However, there are more types of methods with more complex learning scenarios[3, 46].
3.1.1. CLASSIFICATION
Classification is used to identify in which set of categories a new experience can be labelled
according to other experiences. The simplest classification problem is a binary classifi-
cation. It creates a barrier (decision boundary) which separates the data in two different
classes (Figure 3.1).
Figure 3.1: Binary classification.
Giving the data of two classes (triangles and circles)in two dimensions, where a1 and a2
represent two features, it is possible to separate both classes with a straight line (linear
classifier). According to this decision boundary created, it is possible to classify the new
experience (star). The new experience belongs to the class of triangles.
The decision boundary is created by an algorithm, named classifier. This function takes
the unlabelled examples and maps them into labelled, using internal data structures. The
learning task in classification problems is to construct classifiers which are able to classify
unseen examples (x̂) and give them a label (ŷ). A good classifier is the one who, given a
set of experiences - training set -, to create the knowledge, is able to predict/classify new
examples correctly. There are a large number of classifiers and each one can have different
performances depending on the dataset. Six learning classifiers are described bellow:
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Nearest Mean Classifier
The Nearest Mean Classifier (NMC) [47], also known as Minimum Distance Classifier,
is a linear classifier. This classifier calculates the centre of the class. A new experience
is classified according to the closest distance of all class centre (Figure 3.2).
Figure 3.2: Example of Nearest Mean classification.
The centre of the classes are represented by the black triangle and circle. The classifier
separates both classes creating a line equidistant to both centres. The test sample (star)
should be classified as circle.
Giving a set of vectors representing the class y1 (X y1 ), containing m samples with size
n:
X y1 = {−→x y11 ,−→x
y1
2 , ...,
−→x y1m } (3.1)
the centre of a class is determinated calculating the arithmetic mean (X¯ ) of class’s
feature,
X¯ y1 = 1
my1
my1∑
i=1
−→x y1i (3.2)
To classify a new experience x̂, it is calculated the minimum distance dE (Eucledian
distance) between x̂ and the centre of all classes (X¯Y ).
ŷ = argmin
{X¯ y1 ,X¯ y2 ,...,X¯ yz }∈X¯Y
dE (x̂, X¯Y ) (3.3)
dE (
−→a ,−→b ) ≡ ||a−b|| ≡
√
n∑
i=1
(ai −bi )2 (3.4)
k-Nearest Neighbour classifier
The k-Nearest Neighbour (kNN) classifier [48] classifies experiences based on closest
training examples in the feature space. A new experience is classified by a majority
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vote of the neighbourhood. The label more common of the k closest elements is the
label of the new experience (Figure 3.3).
Figure 3.3: Example of k-Nearest Neighbour classification.
The test sample (star) should be classified either to the class of triangles or to the class of
circles. If k = 3 (smaller dashed circle) it is assigned to the class of circles because there
are 2 circles and only 1 triangle inside the inner circle. If k = 5 (bigger dashed circle) it
is assigned to the class of triangles because there are 3 triangles and only 2 circles inside
the inner circle.
Giving a training set D t and a new experience x̂, the method calculates the distance
between the instance x̂ and all training objects (X ,Y ) ∈D t , where X represents the set
of vectors and Y its labels. Once all experiences are sorted by the closest distance, the
new experience is classified based on the majority class of its k nearest neighbours:
Majority voting: ŷ = argmax
{y1,y2,...,yz }∈Y
k∑
i=1
I (yi ,Y ), (3.5)
where yi are the labels of the nearest neighbours of class x̂, k is the number of the
neighbours, and I (yi ,Y )= 1 if yi = Y and I (yi ,Y )= 0 otherwise.
Support Vector Classifier
The Support Vector Machine (SVM) [49] is an algorithm which creates a hyperplane
able to classify all training vectors in two classes. The best choice will be the hyper-
plane that leaves the maximum margin from both classes (Figure 3.4).
The formula for the output of a linear SVM is
ŷ = sg n(−→w ·−→x +b) (3.6)
where −→w is the normal vector to the hyperplane, −→x is the input value and b the y-
intercept. If sg n(−→w ·−→x +b)< 0, the new experience is classified by the class below the
decision boundary, if sg n(−→w ·−→x +b)> 0 it is classified by the class above the boundary.
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Figure 3.4: Example of Support Vector Machine classification in a linearly separable bi-
nary dataset.
The line is the hyperplan and the dashes lines are the margins. The main goal is to max-
imize the distance between margins. Samples on the margin are called the support vec-
tors.
Naïve Bayes Classifier
The Naïve Bayes classifier [50, 51] is based on Bayes’ theorem. This classifier assumes
that the value of a feature is independent of the value of any other feature. This clas-
sifier learns the conditional probability (Equation 3.7) of each class label yi given the
attribute ai :
P (yi |ai )= P (ai |yi )P (yi )
P (ai )
(3.7)
where P (yi |ai ) is the posterior probability of class (target) given predictor (attribute);
P (yi ) is the prior probability of class; P (ai |yi ) is the likelihood which is the probability
of predictor given class; P (ai ) is the evidence probability of predictor.
Classification is then done applying this probability of yi given the particular in-
stance of {a1, a2, ..., an} ∈ A. The predictable class is the one with the highest prob-
ability [52]
ŷ = argmax
yi∈{y1,y2,...,yz }
P (yi )
n∏
j=1
P (a j |yi ) (3.8)
Decision Tree Classifier
Decision tree [53] uses a tree structure. It breaks the dataset into smaller subsets until
the result is a tree with a decision node or a leaf node. A decision node has two or
more branches. A leaf node represents a classification. Decision tree requests several
questions to attributes. Each answer will correspond to a branch. Once the decision
tree is constructed, the classification is straightforward (Figure 3.5).
The simplest algorithm to construct decision trees is the Iterative Dichotomiser 3
(ID3) [53]. The major choice of ID3 algorithm is to find which attribute should be
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Figure 3.5: Example of a decision tree classification.
Nodes (rectangle) represent the features (outlook;humidity;wind), branches are the dif-
ferent answers for a feature and leaves (circle) are the output (yes/no). The test sample
would be sorted downs the rightmost branch of the decision tree and would be classified
as a positive instance (it is possible to play).
the root, the most appropriate to classify examples. This algorithm uses a statistical
test - Information Gain (IG) - that measures how well a given attribute classifies ex-
periences. ID3 uses this measure to select among the different attributes at each step
wile growing the tree.
Before calculating IG, the variable Entropy(H) hve to be determined:
H(D t )=
z∑
i=1
−P (yi ) log2 P (yi ) , yi ∈ Y (3.9)
where D t is the training set for which entropy is being calculated, Y the set of classes
of D t , z the number of different labels and P (yi ) is the probability of yi in Y . If
H(D t )= 0, the set D t is perfectly classified.
IG is calculated according the following equation:
IG(D t , A)=H(D t )−
∑
v∈V (A)
#Dv
#D t
H(Dv ) (3.10)
where H(D t ) is the entropy of the training set D t , V (A) is the set of possible values
for the attribute A, #Dv#D t is the proportion of a value v and the size of the training set
D t and H(Dv ) is the entropy of the subset Dv .
Random Forest Classifier
The random forest classifier [54] uses the bagging method. Bagging is an approach
3.1. LEARN FROM EXAMPLES 19
which creates additional data for training from the original dataset, creating several
subsets, with random samples.
This classifier uses this approach to build a large collection of non-correlated trees.
It selects a few combinations of samples with repetitions to create a decision tree.
To predict a new element, all decision trees created are tested. Then, it counts how
many time each class is predicted. The final result is the class with more votes.
Figure 3.6: Example of a random forest classification.
A- The given dataset contains ten samples. Each sample has their respective label: blue or red. The main
goal is to predict which colour corresponds the new example x̂, in orange. B- Three subsets containing six
samples from the initial dataset is creted. C- For each subset, a decision tree is created. D- In each tree, the
new example x̂ is predicted. The output of tree 1, tree 2 and tree 3 is red, blue and red, respectively. Counting
the number of votes of each label, the final result of this classification is red.
It is important to understand that no classifier is 100% precise to solve all ML problem.
The dataset also affects the classifier’s performance. It also depends on the structure of
the data (high/low bias and variances) and/or if a class has enough training experiences. A
good way to find a classifier with a good performance is using cross-validation, testing their
accuracy (see Section 3.2).
3.1.2. REGRESSION
Regression is used to find a predictive modelling which tries to find a relation between a
dependent (x) and independent variable (y). The model (function) created should fit in
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real data points. In contrast with classification problems (see Section 3.1.1), the output
value, ŷ , is a continuous number.
There are several kinds of regression methods, but the simplest one is the linear model,
represented by a linear equation y =mx+b (Figure 3.7).
The model which has the best fit for a giving training data is calculated by minimizing
the sum of the squares of the vertical distances from the data point to the line - minimiza-
tion of the sum of squared errors (SSE) [55]:
SSE =
m∑
i=1
(yi − yˆi )2 (3.11)
where m is the number of experiences, yi is value of the dependent variable inxi and yˆi
is the value of the dependent variable predicted by the model in xi .
Figure 3.7: Example of linear regression.
The figure shows the linear regression line (black line), created from 9 training examples
(circles). The connection between the data points and the point on the regression line
(red lines) has the same xi value, denoting the distance used to calculate the sum of
squared errors.
The label of the new experience (star) is ŷ , ŷ ∈R.
3.1.3. CLUSTERING
Clustering analysis is used to group a set of experiences into subsets, differentiating each
group (cluster) according to a certain criterion. Examples in the same cluster are more
similar to each other compared with objects in other clusters. There are several clustering
algorithms and, for that reason, it is not easy to have an exact definition of cluster [56, 57].
However, it is typically mentioned as a method to “group unlabelled data objects”.
The main goal of this analysis is to understand how similar (or dissimilar) an individual
experience is from other experiences. There are several different representations such as
partitioned cluster and hierarchical cluster (Figure 3.8).
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Figure 3.8: Cluster analysis.
A- Partitional clustering. The experiences are projected in a 2 dimensional plane. It is possible to group some
examples according to their similarity of the features a1 and a2. B- Hierarchical clustering. Taking the clusters
of A, it is possible to calculate the distances between them and represent it in a diagram tree or dendogram.
Each circle represents an experience and colours are used to distinguish clusters.
3.1.4. DIMENSIONALITY REDUCTION
In Machine Learning problems, most of the data has a high dimension, in other words, a
large number of features (n). In several domains it is important to visualize the data, but,
with a high number of featuresm it can be difficult to extract information. For that reason,
before analyse the data, a dimensionality reduction should be performed. This process
takes the initial data and transforms into a lower-dimensional representation, preserving
some properties of the initial form. The dimensionality reduction can be divided into fea-
ture selection and feature extraction:
1. Feature selection
The feature space is reduced by selecting a subset of revelant features from the origi-
nal data.
2. Feature extraction
The feature space from the original data is reduced through some functional map-
ping. After feature extraction, the features are transformed and reduced. The new
attributes are A′ = {a′1, a′2, . . . , a′nr } , with (nr < n) and A′ = F (A), where F is a map-
ping function, which transforms the attribute A into A′, nr is the number of features
after reduction. There are several feature extraction algorithms, but it will be present
the Principal Component Analysis (PCA) and the t-distributed stochastic neighbor
embedding (t-SNE):
Principal Component Analysis (PCA)
The central idea of PCA [58–60] is to convert the data using an orthogonal trans-
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formation. It will transform the data into a set of uncorrelated linear variables
- principal components. The principal components are ordered according the
degree’s variance. The first principal components contain most of the variation
present in all of the original variables. The succeeding components have the
highest variance compared to the preceding components (Figure 3.9 B)
t-distributed stochastic neighbor embedding (t-SNE)
t-SNE [61] is a nonlinear dimensionality reduction method. It is well suited to
reduce high-dimensional data into the space of two or three dimensions. This
analysis minimizes the divergence between two distributions: construct a dis-
tribution that measures pairwise similarities, where similar samples have a high
probability of being selected; and also construct a distribution that measures
pairwise similarities of the corresponding low-dimensional maps (Figure 3.9 C).
Given that PCA and t-SNE are unsupervised learning, the labels of the data are not
used in the transformation. However, they are used to colour intermediate plots.
Figure 3.9: Visualization of 2,000 samples of the Mixed National Institute of Standards and Technology
(MNIST) dataset using PCA and t-SNE.
A- The MNIST dataset contains information of handwritten digits (from LeCun, Bottou, Bengio, and Haffner
(1998) [62]). PCA (B) and t-SNE (C) are dimensionality reduction algorithms, preserving the proprieties of the
original dataset and allowing the visualization of the data. The figure shows that t-SNE has a better visualiza-
tion compared to PCA.
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3.2. CROSS-VALIDATION
Cross-validation (CV) is a statistical method, used in preticting problems, to evaluate the
accuracy (or error) of a model, being able to evaluate learning algorithms [63].
To perform this analysis, the data is splitted into two groups: the train set, used to learn
a model; and the test set, used to validate the model.
There are a few different types of CV, but the most used is the K -fold cross-validation
[64]. In K -fold cross-validation the data is subdivided into K identical sized folds. For each
K an iteration is performed: a different fold is used for a validation and the K −1 folds to
learn. Each iteration has an error as an output. After all iterations, it is possible to calcu-
late the average error rate of the model, giving an idea of how well the model generalizes
(Figure 3.10).
Figure 3.10: Representation of K -fold cross-validation.
A- Dataset contains experiences of two classes. B- Data is reshuffled randomly to reduce the bias. C- Data is
subdivided into five identical sized subsets (K = 5). D- From the five folds created, four are used to train the
model and the last fold for evaluation. E- The output is the average error rate of a classifier, giving an idea of
how well is the classifier’s performance. In order to reduce the error rate, this process can be repeated, giving
a more accurate average of each evaluation. In each repetition, the data is reorganized (B).
The number of folds (K ) to use is arbitrary, but there are some points to take into ac-
count: if a large value is used, the bias of the true error rate estimator will be small, but
the variance of the true error rate will be large and it will take too many time, due the low
number of experiments in each fold; If a small number of folds is used, the computation
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time is reduced, the variance of the estimator will be small, but the bias of the estimator
will be large. A common choice for this method is use K = 10.
The output of each iteration is the estimated accuracy of the model. The accuracy of
a classifier C is the probability of classifying correctly a random experience, i.e., acc =
P (C (x̂)= ŷ), where x̂ is the experience and ŷ its class.
In CV, the accuracy (acc) corresponds to the number of correct classifications, divided
by the number of instances in the dataset [64]:
accCV = 1
m
∑
(ŷ ,yi )∈D t
I (C (D t , ŷ), yi ) (3.12)
where m is the number of instances of the training set D t , C (D t , yu) is the mapping
function of the classifier C in the train set (D t ), having ŷ as a result, and I is an indicator
function where I (a,b)= 1 if a = b and 0 otherwise.
The error (ERR) of a model can be calculated by:
ERR = 1−acc (3.13)
Another way to evaluate the viability of a model is using the area under the curve (AUC)
of a receiver operating characteristic (ROC) curve [65]. Considering a two-class classifica-
tion problem, in which the outcomes are pr esence or absences of a disease, it can have
four possible solutions (Table 3.1): samples carrying the disease and the model can classify
correctly its presence (True Positive (TP)), however, sometimes can happen to be classified
as healthy (False Negative (FN)). On the other hand, some samples without the disease will
be correctly classified as negative (True Negative (TN)), but some cases without the disease
will be classified as positive (False Positive (FP)).
The ROC curve is created by plotting the False Positive Rate (or 1−Speci f i ci t y) against
the True Positive Rate (or Sensi t i vi t y):
sensi t i vi t y = T P
T P +F N speci f i ci t y =
T N
T N +F P (3.14)
The curve always goes through two points: (0,0) and (1,1) (Figure 3.11). The model is
considered better than other if the AUC is greater. If the AUC is equal to 1, it means that the
test is 100% accurate because both specificity and sensitivity are 1, without false negative
and false positive values. On the other hand, if a test cannot assess between correct and
incorrect, the curve will correspond to a diagonal, where its AUC is equal to 0.5. The typical
AUC of a ROC curve is between 0.5 and 1.
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Table 3.1: Confusion matrix used to tabulate the predictive capacity of presence/absence models.
It can have four different outcomes: True Positive (TP) - presence observed and predicted by model;
False Positive (FP) - absence observed but predicted as present; False Negative (FN) - presence ob-
served but predicted as absent; True Negative (TN) - absence observed and predicted by model.
Predicted
Presence Observed
Actual
Presence TP FN
Absence FP TN
Figure 3.11: Representation of three ROC curves.
The green curve (AUC = 1) represents the best model, while the red curve
(AUC = 0.5) represents the worst one. The blue curve is a positive predic-
tive model.
The error (ERR) of a model can be calculated by:
ERR = 1− AUC (3.15)
3.3. DISSIMILARITY REPRESENTATION
In many cases it is not easy to evaluate a dataset and compare its samples. It can be con-
venient to understand how different two samples are, that is, the distance (or dissimilarity)
between them. Considering d(a,b) the dissimilarity of the sample a from b, then
d(a,b) > 0 if a 6= b
d(a,b) = 0 if a = b
d(a,b) = d(b, a)
d(a,b) ≤ d(a,c)+d(b,c)
(3.16)
If the dissimilarity measures satisfy the four conditions above, the dissimilarity measure
is a metric and the term distance is usually used [66].
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Compare all samples of a dataset will generate a distance matrix [67, 68]. Here, a dis-
tance matrix is considered as a 2D array containing the distances, taken pairwise, between
the samples of a dataset.
Matrix 3.17 represents an example of an array M(m×n), m rows and n columns, and it is
filled with Boolean data, B = {0,1}. Each row is a vector (−→x i ) and each column an attribute
(a j ).
M=

a1 a2 a3 a4 a5 a6 ... an
−→x 1 B B B B B B . . . B
−→x 2 B B B B B B . . . B
−→x 3 B B B B B B . . . B
−→x 4 B B B B B B . . . B
...
...
...
...
...
...
...
. . .
...
−→x m B B B B B B . . . B

(3.17)
Calculating the distance d through the matrix M, will map the distances between all
samples of the dataset, creating a distance matrix (Matrix 3.18). The distance matrix is
a square matrix with size m ×m, symmetric, filled with non-negative elements and the
diagonal elements are equal to zero. These proprieties are justified by the equations 3.16.
d(M)=

0 d(−→x 1,−→x 2) d(−→x 1,−→x 3) d(−→x 1,−→x 4) · · · d(−→x 1,−→x m)
d(−→x 2,−→x 1) 0 d(−→x 2,−→x 3) d(−→x 2,−→x 4) · · · d(−→x 2,−→x m)
d(−→x 3,−→x 1) d(−→x 3,−→x 2) 0 d(−→x 3,−→x 4) · · · d(−→x 3,−→x m)
d(−→x 4,−→x 1) d(−→x 4,−→x 2) d(−→x 4,−→x 3) 0 · · · d(−→x 4,−→x m)
...
...
...
...
. . .
...
d(−→x m ,−→x 1) d(−→x m ,−→x 2) d(−→x m ,−→x 3) d(−→x m ,−→x 4) · · · 0

(3.18)
There are many different ways to measure dissimilarity and, for that reason, there are
many different dissimilarity transformations. It depends upon the application involved.
For vectors of binary data, −→x i and −→x j , these may be expressed in terms of the number of
a, b, c and d where
a is equal to the number of occurrences of −→x i = 1 and −→x j = 1
b is equal to the number of occurrences of −→x i = 0 and −→x j = 1
c is equal to the number of occurrences of −→x i = 1 and −→x j = 0
d is equal to the number of occurrences of −→x i = 0 and −→x j = 0
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This is summarised in Table 3.2.
Table 3.2: Co-occurrence table for binary variables
−→x i
1 0
−→x j 1 a b0 c d
Two metrics often used are presented to map binary data into distances matrix:
1. Hamming distance
The Hamming dissimilarity [69] is defined by the ratio of mismatches among their
pairs of variables:
dH =
#(−→x i 6= −→x j )
#[(−→x i 6= −→x j )∪ (−→x i =−→x j )]
≡ b+ c
a+b+ c+d (3.19)
2. Jaccard distance
The Jaccard dissimilarity[70] is defined by the ratio of mismatches among the non-
zeros’s pairs:
d J =
#[(−→x i 6= −→x j )
#[(−→x i 6= 0)∪ (−→x j 6= 0)]
≡ b+ c
a+b+ c (3.20)
Equation A.1, in Appendix A.1, shows 9 examples to compare both metrics.
3.4. FEATURE RANKING
In Machine Learning, feature ranking is used to sort features, by relevance, for a certain
class in a two class task. Different methods have been developed depending on the applica-
tion [71]. However, this can bring some issues. Different methods will generate a different
feature ranking of the same data.
A recent study [72] compares the three ranking algorithms for binary features to under-
stand which one generates the most ’correct’ ranking. Using five artificial data and four
real-life data they concluded that the diff-criterion algorithm got the most correct perfor-
mance.
Diff-criterion [73] uses a distance between probability distributions of two classes. It
estimates the importance of the i th feature as:
−→
R = p(ai = 1|y1)−p(ai = 1|y2) (3.21)
28 3. MACHINE LEARNING
where p(ai = 1|y1) and p(ai = 1|y2) are the probability of a feature has a 1 in the classes
y1 and y2.
−→
R is a vector containing the scores of a feature ai . Each score is a value between -
1 and 1. The higher the score, the greater importance. If a score is zero, it means the feature
has the same probability of belonging in both classes. Sorting
−→
R , it is possible to have the
attributes sorted according to that parameter.
4
DATA
4.1. DATA GENERATION
The following work was developed using an exclusive data collection, compiled from sev-
eral studies (Table 4.1). They correspond to a compendium of IM screens in mice. The data
from each study are available online and can be downloaded.
Each study uses several samples of tumour development. All of them were infected with
an integration element (e.g. a retrovirus or a transposon). After that, insertions are identi-
fied and mapped. For each gene, two windows with 10 kilobase (kb), up- and downstream
of its location, were created. Window space is the name given to the distance between the
first bp of a window upstream of the gene and the last bp of a window downstream of the
gene (comprising the gene). It was verified, in all window spaces, whether it is carried an
insertion or not. This results in a Boolean matrix: if an insertion is included in a window
space, the gene will contain a 1, otherwise, the gene has a 0. All the information is stored in
a .csv file (Figure 4.1).
4.2. DESCRIPTION
This dataset contains information collected across 54 studies, obtained from 38 papers (Ta-
ble 4.1). This compilation contains 7,037 samples of IM data organized in 14 types of can-
cer. To the best of my knowledge, this is the first analysis, using DNA integration, to span
an extensive number of independent tumours.
Each study contained between 17 and 3853 samples. They are related to one type of
cancer, resulting in 13 specific ones and in one additional type labelled “Various”, which
29
30 4. DATA
Figure 4.1: Organization of data generated.
A- Each sample represents the genome of a cancer cell in the mouse. The mouse is infected by an integrating
element which inserts, randomly, pieces of DNA in the genome. After mapping the insertions, it is possible
to identify their location. B- For each gene, two windows of 10 kb were created, located up- and downstream
of the gene. In the area covered between windows - window space -, it was verified whether an insertion was
integrated or not. C- The previous analysis was stored in a matrix, where for each sample it is identified which
genes have an insertion in its vicinity. Insertion A is not covered by any windows. Insertion B (downstream of
the gene), insertion C (within the gene) and insertion D (upstream of the gene) are captured by the window
space of gene 3, gene 4 and gene 6, respectively. For this reason, entries for gene 1, gene 2 and gene 5 are 0,
and gene 3, gene 4 and gene 6 are 1.
contain information of more than one cancer type. All types of cancer are described below:
Basal cell carcinoma
Basal cell carcinoma (BCC) it is the most common type of skin in cancer (80%)2 and
one of the most common type of cancer in humans. It is typically developed on ar-
eas that have been exposed in the sun. It growths slowly and spreads to the nearest
tissues, but it is rare to spread to other body parts.
Colorectal
Colorectal cancer starts in the colon or the rectum (part of the large intestine). It is
the third most commonly diagnosed cancer in males and the second in females [2].
Glioblastoma
Glioblastoma multiforme (GBM) the most common type of cancer in the nervous
system. It is formed from glial tissues of brain and spinal cord.
Hematopoietic
Hematopoietic stem cells (HSC) can develop all types of blood cells, producing an
enormous number of blood cells every day.
2http://www.cancer.org/cancer/skincancer-basalandsquamouscell/detailedguide/skin-cancer-basal-and-
squamous-cell-what-is-basal-and-squamous-cell, accessed: July 2015
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Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is the
second leading cause of cancer death in males [2].
Lymphoma
Lymphoma is a cancer which starts in the lymphoma system, a part of the immune
system.
Malignant peripheral nerve sheath
Malignant peripheral nerve sheath tumour (MPNST) is a variety of soft tissue tu-
mours. It is a rare tumour and appears in a neuron cell, the Schwann cells.
Mammary
Mammary cancer, also known as breast cancer in Human, is originated in the mam-
mary gland. It is the most common cause of death in females.
Medulloblastoma
Medulloblastoma is the most common paediatric primary brain tumour. It can begin
in the lower part of the brain and spread to the spine or other part of the body.
Pancreatic
Pancreatic cancer starts in the pancreas. It is one of the most lethal type of cancer
because usually is only diagnosed in advanced stages [74].
Sarcoma
Sarcoma is a type of cancer that begins in bone or in the soft tissues of the body (e.g.
muscle, fibrous tissue, cartilage, etc).
Squamos cell carcinoma
Squamos cell carcinoma (SCC) is the second most common skin cancer, after BCC3.
Like BCC it also develops on sun-exposed areas. It growth more likely into deeper
layers of skin and are it is more frequent to spread to other body parts, comparing
with BCC, but it is still uncommon.
T-cell acute lymphoblastic leukaemia
T-cell acute lymphoblastic leukaemia (T-ALL) starts in one of the lymphocytes’ cate-
gory: T-cell. It is a type of white blood, present in the immune system.
3http://www.skincancer.org/skin-cancer-information/squamous-cell-carcinoma, accessed: July 2015
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In general, each tumour type has a few thousands samples (7037 in total) and all of
them refer to the mouse genome, representing 22019 genes.
Commonly the genome has only a few insertions. Genes with insertions in their vicinity
represent 0.0759% of the entire data.
4.3. PRE-PROCESSING
This data contains information about 13 different tumour types and an extra containing
analysis of several cancer types, named “various” [79, 82, 83]. For the purpose of the present
work, this last group was too ambiguous, not giving information about a particular tumour
type. For this reason, this set, representing 86 samples, was removed.
In a first step, the distributions of insertions per sample and gene were analysed (Fig-
ures 4.2a and 4.2b). In general, it is shown that, in both situations, it is more frequent to
have a few insertions. In fact, more than 3,000 samples have less than 3 insertions and
more than 10,000 genes have less than 4 insertions.
The insertion can happen in the entire genome. However, it does not mean it is close to
a gene. Therefore, the window space may not catch the integration. In order to have more
informative samples, the median of insertions’ frequency was used as a threshold. Samples
which have less than 4 insertions were removed. In some tumour types, this elimination
results in a loss of more than 60% of samples, or even the total loss of samples (Table 4.2).
In total, this threshold excludes 3,244 samples.
After the samples’ removal, some tissues had just a few numbers of examples. It is not
valid to perform an analysis between two classes which have a large difference in num-
bers of samples (e.g. compare lymphoma versus SCC, with 98.8% less samples). To have a
statistically significant analysis, all tumour types which have less than 10% of lymphoma’s
sample size were excluded. In other words, all cancer types which have less than 130 sam-
ples, after the threshold process, were removed. They are: basal and squamos cell carci-
noma;glioblastoma; mammary; pancreatic; sarcoma and squamos cell carcinoma (corre-
sponding, together, 293 samples).
If a gene has a few insertions, it is not too informative. It means that some genes are
not involved in the tumourogenesis’ process. It is more interesting if a gene has a lot of
insertions in the vicinity of a gene in independent tumours (common insertion site (CIS)).
Similarly to the samples’ analysis, a threshold it was used to remove that genes that are not
so interesting. This threshold corresponds to the median of the frequencies. Genes which
have less than 5 insertions were removed. This removal corresponds to 14,268 genes.
After all this cut-off, the data used in the following project corresponds to a Boolean ma-
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Table 4.1: List of studies collected for this project regarding to insertional mutagenesis screens.
It contains 14 different tumour types, with several samples, totalling 7037.
Study name Tumour type
Number of
Samples
Reference
1 BARD_NATURE-GENETICS_2014_ALL Hepatocellular carcinoma 250 [75]
2 BENDER_CANCER-RESEARCH_2009_BEN Glioblastoma 21 [76]
3 BERQUAM-VRIEZE_BLOOD_2011_CD4 T-ALL 38 [77]
4 BERQUAM-VRIEZE_BLOOD_2011_LCK T-ALL 27 [77]
5 BERQUAM-VRIEZE_BLOOD_2011_VAV T-ALL 36 [77]
6 CESANA_MOL-THERAPY_2014_ALL Hematopoietic 277 [78]
7 COLLIER_CANCER-RESEARCH_2009_LYM-LEU Various 59 [79]
8 COLLIER_NATURE_2005_ALL Sarcoma 28 [80]
9 DUPUY_CANCER-RESEARCH_2009_HCC Hepatocellular carcinoma 11 [81]
10 DUPUY_CANCER-RESEARCH_2009_SCC Squamos cell carcinoma 17 [81]
11 DUPUY_NATURE_2005_ALL Various 16 [82]
12 FRIEDEL_PLOS-ONE_2013_ALL Various 11 [83]
13 GENOVESI_PNAS_2013_MB Medulloblastoma 85 [84]
14 HUSER_PLOS-GENETICS_2014_GIM1 Lymphoma 28 [85]
15 KENG_HEPATOLOGY_2013_COMB Hepatocellular carcinoma 162 [86]
16 KENG_NATURE-BIOTECHNOLOGY_2009_HCC Hepatocellular carcinoma 69 [87]
17 KOOL_CANCER-RESEARCH_2010_CDK Lymphoma 1354 [88]
18 KOSO_CANCER-RESEARCH_2014_P53 Medulloblastoma 27 [89]
19 KOSO_CANCER-RESEARCH_2014_WT Medulloblastoma 17 [89]
20 KOSO_PNAS_2012_CELL Glioblastoma 26 [90]
21 KOSO_PNAS_2012_TUMOUR Glioblastoma 70 [90]
22 KOUDIJS_GENOME-RESEARCH_2011_MULV Mammary 48 [91]
23 KOUDIJS_GENOME-RESEARCH_2011_SB Lymphoma 379 [91]
24 LATOWSKA_ANC_2013_MB Medulloblastoma 41 [92]
25 MANN-K_PNAS_2012_KRAS Pancreatic 21 [93]
26 MARCH_NATURE-GENETICS_2011_ALL Colorectal 445 [94]
27 ODONNELL_PNAS_2012_ALL Hepatocellular carcinoma 24 [95]
28 PEREZ-MANCERA_NATURE_2012_SB10 Pancreatic 58 [96]
29 PEREZ-MANCERA_NATURE_2012_SB13 Pancreatic 197 [96]
30 QUINTANA_INVESTIGATIVE-DERMATOLOGY_2013_SB11 Basal and Squamos cell carcinoma 75 [97]
31 RAD_SCIENCE_2010_ALL Hematopoietic 91 [98]
32 RAHRMAN_NATURE-GENETICS_2013_NF Malignant peripheral nerve sheat 267 [99]
33 RAHRMAN_NATURE-GENETICS_2013_PNST Malignant peripheral nerve sheat 100 [99]
34 RANZANI_NATURE-METHODS_2013_ALL Hepatocellular carcinoma 30 [100]
35 STARR_PNAS_2011_ALL Colorectal 96 [101]
36 STARR_SCIENCE_2009_DATASET1 Colorectal 42 [102]
37 STARR_SCIENCE_2009_DATASET2 Colorectal 93 [102]
38 THEODOROU_NATURE-GENETICS_2007_ALL Mamary 136 [103]
39 UREN_CELL_2008_P19KO Lymphoma 617 [104]
40 UREN_CELL_2008_P53KO Lymphoma 326 [104]
41 UREN_CELL_2008_WT Lymphoma 454 [104]
42 VAN-DER-WEYDEN_BLOOD_2011_BCP-ALL Lymphoma 15 [105]
43 VAN-DER-WEYDEN_BLOOD_2011_T-ALL Lymphoma 19 [105]
44 VAN-DER-WEYDEN_CANCER-RESEARCH_2012_KO Lymphoma 109 [106]
45 VAN-DER-WEYDEN_IJCR_2012_KO Lymphoma 92 [107]
46 VAN-DER-WEYDEN_IJCR_2012_POOLED Lymphoma 126 [107]
47 VAN-DER-WEYDEN_ONCOGENE_2013_HET Lymphoma 116 [108]
48 VAN-DER-WEYDEN_ONCOGENE_2013_HOM Lymphoma 9 [108]
49 VASSILIOU_NATURE-GENETICS_2011_NPM1C Lymphoma 85 [109]
50 VASSILIOU_NATURE-GENETICS_2011_NPM1WT Lymphoma 30 [109]
51 WONG_NATURE-GENETICS_2014_CUX1 Lymphoma 70 [110]
52 WU_NATURE_2013_PTCH Medulloblastoma 140 [111]
53 WU_NATURE_2013_TP53 Medulloblastoma 33 [111]
54 ZANESI_BLOOD_2013_CD19-CRE Lymphoma 24 [112]
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Table 4.2: Samples’ size reduction of each tumour types.
(a) Number of samples of each tumour type before the data treatment.
(b) Number of samples of each tumour type after the data treatment.
? Type of tumour discarded.
Tumour type
Number of
Samples (a)
Number of
Samples (b)
Removal
percentage
(%)
? Basal and squamous cell carcinoma 75 73 2.67
Colorectal 676 623 7.84
? Glioblastoma 117 95 18.80
Hematopoietic 368 140 61.96
Hepatocellular carcinoma 546 453 17.03
Lymphoma 3853 1308 66.05
Malignant peripheral nerve sheath 367 329 10.35
? Mammary 184 24 86.96
Medulloblastoma 343 333 2.92
Pancreatic 276 228 17.39
? Sarcoma 28 0 100.00
? Squamous cell carcinoma 17 16 5.88
? T-ALL 101 85 15.84
trix of 3,414 objects (samples) by 7,751 features (genes) organized into 7 classes (colorectal,
hematopoietic, hepatocellular carcinoma, lymphoma, malignant peripheral nerve sheath,
medulloblastoma and pancreatic). Figures 4.2c and 4.2d shows the insertions’ frequency
after this pre-processing.
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(a) Insertions per sample before the processing. (b) Insertions per gene before the processing.
(c) Insertions per sample after the processing. (d) Insertions per gene after the processing.
Figure 4.2: Distribution of insertions’ frequency represented in histogram and boxplot.
a- Number of insertions per sample before the processing: Data contains 7037 values; the median is 4; the
mean is 17.51; the * means that there are 12 points bigger than 244. b- Number of insertions per gene before
the processing: Data contains 22019 values; the median is 5; the mean is 5.9; the * means that there are
130 points bigger than 28. c- Number of of insertions per sample after the processing: Data contains 3414
values; the median is 13; the mean is 18.34; the * means that there are 13 points bigger than 86. d- Number of
insertions per gene after the processing: Data contains 7751 values; the median is 7; the mean is 8.08; the *
means that there are 91 points bigger than 27.5.
+ - Mean of the values. | - Median of the values.

5
METHODOLOGY
For the several steps of the work, Matrix laboratory (MATLAB)[113] was used. It is a high-
performance language for technical computing, integrating computation, visualization and
programming.
5.1. DATA
The pre-processing of the data was done using MATLAB. The data are organized in a ma-
trix, containing the information of 3,414 samples over 7,751 genes (see Section 4.3). Each
sample is characterized by one label, representing the tumour type (colorectal, HSC, HCC,
lymphoma, MPNST, medulloblastoma and pancreatic).
5.2. DATA TRANSFORMATION
In order to understand differences between samples, the distance method may be per-
formed. Comparing two samples (two boolean vectors), three different situations can oc-
cur: a gene does not have insertions in both samples (match0−0), a gene have insertion in
both samples (match1−1), or a gene have one insertion in only one of the samples (mi smatch):
[−→x 1 1 1 0 0 0 0 0 0 0 1
−→x 2 0 1 0 0 0 0 1 0 0 0
]
(5.1)
Analysing the samples−→x 1 and−→x 2 of Matrix 5.1, it has six match0−0, one match1−1 and
three mi smatch.
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Since the integrations affect only a few genes in the whole genome it is important to fo-
cus on the differences between them. Four different metrics were applied: two known from
the literature (Hamming [69] and Jaccard distance [70]) and two new metrics were devel-
oped and implemented (gene dependent method (GDM) and gene independent method
(GIM)).
The Hamming distance takes into account the mismatch genes and compares with all
other situations. On the other hand, the Jaccard distance also takes into account the mis-
match genes, but it ignores the match0−0. This can be an advantage because this metric
will take in consideration all genes that have an insertion at least in one sample. The Ham-
ming and Jaccard distance were calculated using the function pdist from the Statistics and
Machine Learning Toolbox of MATLAB.
These two metrics do not have in consideration the biological meaning of the data.
To take into account this factor, two new metrics were developed - GDM and GIM. Both
metrics are described in the next two sections.
5.2.1. GENE DEPENDENT METHOD
The previous methods consider all genes with the same weight, but it could be relevant
distinguish them. For example, having three samples containing information about two
genes: the first sample is the control, without mutations; the second has a mutated gene
implied in the development of a disease; and the third one has a mutation in a gene which
is not involved in the disease phenotype (Matrix 5.2)

Gene∗1 Gene2 Out put
Sample0 0 0 Healthy
Sample1 1 0 Not healhy
Sample2 0 1 Healthy
 (5.2)
*gene implied in the disease development.
1 - gene mutated, 0 - gene not mutated.
In order to compare the effect of mutation in a disease, a comparison between control
(Sample0) and the test samples (Sample1 and Sample2) should be done. In this example,
(Sample0 and Sample2) are more similar, not developing the disease. Otherwise, since
the samples (Sample0 and Sample1) have different phenotypes, they are more dissimilar.
To take into account the weight of each gene, the GDM was developed. From our data,
it is considered a gene with more weight a gene with more insertions in its vicinity.
5.2. DATA TRANSFORMATION 39
Comparing two samples, this method goes through all features to compare if, in a po-
sition i , they have the same or different value. If the value is different(mi smatch), it is
multiplied by the weight of that feature. Weight (
−→
W ) is a vector corresponding to the num-
ber of insertions in the vicinity of a gene, across all samples. In other words, is the sum of
columns of a matrix:
−→
W =
m∑
i=1
−→x i (5.3)
where (−→xi ) is a vector, corresponding to a sample.
The GDM distance (dGDM ) of two samples a and b is defined by:
dGDM (a,b)=
n∑
i=1
δ(ai ,bi )×−→W i (5.4)
where δ is an indicator function where δ(a,b)= 1 if a 6= b and 0 otherwise.
Figure 5.1 shows and example of a dataset and its output using this metric.
Figure 5.1: Example of a dataset and its respective distance matrix using GDM metric.
A -Example of a dataset containing 13 samples, over 7 attributes, organized in 3 classes.
−→
W is a vector with
the weights of a feature, in other words, the number of insertions in the vicinity of a gene. B- Distance matrix
generated from (A) using the GDM distance.
The key of this metric is the weight of a gene. Let us compare the pair dGDM (x1, x3)
with the pair dGDM (x1, x8). In the first pair, only one attribute is different (a2). a2 is a gene
that was only mutated one time. On the other hand, the second pair also was one different
attribute (a5), but this gene has a large number of insertions in its vicinity. For that reason,
the pair dGDM (x1, x8) has a greater distance, because the different gene seems to be really
important.
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5.2.2. GENE INDEPENDENT METHOD
Data contains information about integration elements in the mouse genome. Given the
high dimension of the genome, only a few genes will be affected by an insertion. In fact, in
the entire data, only 0.0759% of genes has insertions in its vicinity. So, when comparing two
samples, it is very common to find a match0−0 and unusual to find a match1−1. Therefore,
the match1−1 between samples may be important.
In order to take into account the differences between all possible pairs of match and
mismatch in the dataset, a new metric - the GIM - was developed. This metric calculates
the probability of a match and mi smatch happen in the whole data. This probability will
be used as a weight.
Selecting two samples x1 and x2 the algorithm calculates the number of matches of
zeros (match0−0), matches of ones (match1−1) and mismatches (mi smatch):
match0−0 =
n∑
i=1
I (x1i , x2i ), x1i = 0
match1−1 =
n∑
i=1
I (x1i , x2i ), x1i = 1
mi smatch =
n∑
i=1
δ(x1i , x2i )
(5.5)
where n is the number of features and I and δ are indicator functions. I (a,b)= 1 if a = b
and 0 otherwise. In contrast, δ(a,b)= 1 if a 6= b and 0 otherwise.
The total number of matches of zeros (N0−0), matches of ones (N1−1) and mismatches
(N1−0) of the entire data is given by the sum of all the pairwises calculated.
N0−0 =
p∑
i=1
match0−0 i
N1−1 =
p∑
i=1
match1−1 i
N1−0 =
p∑
i=1
mi smatchi
(5.6)
where p is the number of samples’ pairwises.
The total number of matches and mismatches is given by N
N =N1−1+N1−0+N0−0 (5.7)
The GIM distance (dG I M ) of two samples a and b focus in its different elements is de-
fined by:
dG I M (a,b)= 1N1−0
N
×
n∑
i=1
δ(ai ,bi ) (5.8)
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Figure 5.2: Example of a dataset and its the respective distance matrix using GIM metric.
A -Example of a dataset containing 13 samples, over 7 attributes, organized in 3 classes. B - It counts the
number of pairs existent in the dataset (N0−0 - 434, N1−0 - 154 and N1−1 - 49) C- Distance matrix generated
from (A) using the GIM distance.
where δ is an indicator function where δ(a,b) = 1 if a 6= b and 0 otherwise. This trans-
formation results in a redefine form of Hamming distance.
Figure 5.2 shows an example of a dataset and its output using GIM distance.
Example of a dataset and its respective distance matrix using GDM metric.
Let us compare the pairs dGDM (x2, x3), dGDM (x2, x4) and dGDM (x5, x8). All of them con-
tain three mismatches and all attributes have the same weight. Once this algorithm only
has in consideration the ration between mismatches values, the distance between the three
pairs are the same.
The pre-processed dataset (see Section 4.3) was transformed using the following met-
rics: dH , d J , dGDM and dG I M . Appendix A.2 contains the heat map of the distance matrices
generated by the four metrics. These transformations are used in the unsupervised an su-
pervised learning methods.
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5.3. UNSUPERVISED LEARNING
Unsupervised learning approaches reduces the size of a data, being helpful to its visualiza-
tion. Feature extraction takes the original dataset and reduces its dimension preserving the
proprieties of the initial data. In general, data are reduced into two dimensions (2D), so it
can be visualized in a plot.
PCA [58–60] has been widely used to reduce the number of features and t-SNE [61] is a
more recent approach and has shown to be very efficient. These two methods were done
across the four transformation data, reducing their dimensionality into 2D. This step was
done using the toolbox: Matlab Toolbox for Dimensionality Reduction4.
5.4. SUPERVISED LEARNING
Supervised learning has been used to classify data, using a classifier. It is possible to eval-
uate its accuracy, using cross-validation (CV). There are dozens of different learning clas-
sifiers and each one has different performance depending the data. The ones who fits the
best to the data, should be selected.
In order to select which classifiers will perform the supervised learning, two different
cancer types with identical number of samples were selected. It was taken into account that
both cancer types came from distinct organs. The tumour types selected were hematopoi-
etic (140 samples) and pancreatic (228 samples).
Seven widely used classifiers were selected and tested (Table 5.1). The performance of
each model was calculated using CV (k=10 and 30 repetitions). To reduce the computa-
tion time, in the next steps, the top three classifiers were selected (Figure 5.3). This top
was determined by the average of the error rate of a ROC curve. The classifiers chosen for
subsequent steps were NMC, kNN and SVM. This evaluation was done using the toolbox
PRTools [114].
Table 5.1: Functions of PRTools used and their respective name.
Function Classifier Name Reference
nmc Nearest Mean Classifier [47]
knnc k-Nearest Neighbour [48]
svc Support Vector Machine [49]
naivebc Naïve Bayes Classifier [50, 51]
ldc Linear Bayes Normal Classifier [50]
treec Decision Tree [53]
randomforest Random Forest [54]
4http://lvdmaaten.github.io/drtoolbox/
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Figure 5.3: Classifiers’ error rate.
Seven classifiers were tested, using two classes with identical size. The best three classifiers, with less error
rate, were selected for the next steps. Mean of the error rate: NMC: 0.098; KNN: 0.119; SVM: 0.245; Naïve
Bayes: 0.487; LDC: 0.502; Decision tree: 0.349; Random fores: 0.346
The supervised learning method was done across the four transformed data. Since CV
evaluates the accuracy in binary classification, different subdatasets combining two tu-
mour types were created (totalizing 21 subsets). The k-fold cross-validation was performed
using the top three classifiers across those subdatasets. The number of folds applied are
k = 10. Since the standard deviation of the first analysis has low values (Figure 5.3), the
number of repetitions were reduced to fives. The output of each CV is the error rate of a
ROC curve. This step was done using the toolbox PRTools [114].
5.5. GENE RANKING
The main goal of feature ranking is to sort them, according to their importance, in a given
class. It is performed in two class problems. In this work, features are represented by genes.
The main aim is to find which genes are involved in a specific cancer type. For this
reason, the analysis will be done comparing one class against the rest of the dataset. If
samples of a tumour type has a gene containing insertions in its vicinity, and, in contrast,
the rest of the samples do not have insertions for the same gene, this gene may be important
for that type of cancer (Figure 5.4). This approach fits with the diff-criterion algorithm [73].
As an output of this algorithm, each feature will be associated to a score. Greater the score,
the greater the importance of the feature to that class.
For this analysis, new subdatasets were created (totalizing 7 subdatasets). Each sub-
dataset contains information of a tumour type and the rest cancer types are relabeled as
second class. The diff-criterion algorithm was implemented and run through the seven
subdatasets created.
Each subdataset will have it own gene scores. This score will change according to the
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Figure 5.4: Example of feature ranking using diff-criterion algorithm.
The data given contains eight samples over seven attributes, organized in two classes. The sorted attributes
according to their importance is a2, a6, a4, a3, a1, a5, a7.
importance of the gene to a specific tumour type. Once all genes have their score, in each
subdataset, the 15 greater scores are selected. This selection corresponds to the top 15
genes involved to a specific cancer type.
6
RESULTS AND DISCUSSION
The main goal of this project is to understand which genes may have an important role
in the development of a specific tumour type. To achieve this goal, the data were trans-
formed. Then, unsupervised and supervised approaches were used to find if the data have
structure, allowing to distinguish different tumour types. If it is possible to differentiate dif-
ferent cancer types, a feature ranking may be performed, in order to find which genes may
be more activated in those tumour types.
6.1. UNSUPERVISED LEARNING
Unsupervised learning methods, in particular feature extraction, allow to visualise the data
into lower dimensions. Two approaches were used across the four data transformation:
PCA [58–60] and t-SNE [61].
The results of PCA are shown in Figure 6.1.
The Hamming and GIM transformations have identical representations. Once both
transformations have a linear correlation of 1.0, it means both represent the same. For
that reason, it was expected that they had similar outputs.
The GDM seems to have a symmetric representation of GIM and Hamming transfor-
mations. In all cases, it is possible to visualise an aggregation of pancreatic tumour, as well
as, HCC. The lymphoma tumour has an agglomeration, however it also has some dispersed
points.
The Jaccard transformation has the most different representation. The second principal
component of this transformation has low variation.
In general, PCA does not show clear clusters of the tumour types.
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(a) Hamming (b) Jaccard
(c) GDM (d) GIM
Figure 6.1: Result of Principal Component Analysis (PCA) across the transformed data.
The Hamming distance and the gene independent method (GIM), seem to have identical results. On the
other hand, gene dependent method (GDM) looks to be symmetric to them. The Jaccard distance shows to
have the most different result. In any situation is possible not to have a clear visualization of clusters.
The results of t-SNE are shown in Figure 6.2.
t-SNE has a non-convex objective function. For that reason, running two times the
same data will generate different representations. In fact, even GIM and Hamming trans-
formations do not have the same illustration, they are identical. A numerous substructures
are represented, prevailing the pancreatic tumour and the lymphoma tumour in the shape
of some clusters.
GDM transformation creates small clusters of lymphoma tumour. However, HCC tu-
mour seems to be agglomerate in the bottom of the figure.
Jaccard transformation has a lot of sparse points. It can happen because most of the
distance between samples is equal to one. However, it is possible to visualise an aggregation
of HCC tumour.
In general, t-SNE has a large overlaping tumours and it does not show clear clusters of
the tumour types.
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(a) Hamming (b) Jaccard
(c) GDM (d) GIM
Figure 6.2: Result of t-distributed stochastic neighbor embedding (t-SNE) across the transformed data.
All the transformed data show that data have some structure. However, there is an overlapping of tumour
types. The Hamming distance and the gene independent method (GIM), have similar results, showing some
aggregation of lymphoma and pancreatic tumour types. Gene dependent method GDM has more substruc-
tures prevailing lymphoma tumours. The Jaccard transformation has a lot of clusters of lymphoma and an
HCC is clearly defined.
Both unsupervised methods do not give a lot information. PCA as a terrible visualiza-
tion and t-SNE, despite showing some structure, it is not satisfied. These approaches are
not sufficient. For that reason, supervised methods will be done.
6.2. SUPERVISED LEARNING
Supervised learning methods, contrary to the unsupervised learning methods, use the sam-
ples’ label for its analysis. The label corresponds to a tumour type. It was evaluated if a
classifier is able to distinguish two different tumour type. Cross-validation (CV) was used
to evaluate the accuracy of three classifiers - NMC, kNN and SVM -, over the four trans-
formed data.
Figure 6.3 shows violins plots of the CV error rate. Each point is the value of a classifier’s
error rate in a binary classification. A low error rate value, is a classifier has a good accuracy.
The values of the individual points in the figure are presented in Appendix B.
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(a) Hamming - NMC: 0.32; kNN: 0.26; SVM: 0.24 (b) Jaccard - NMC: 0.16; kNN: 0.18; SVM: 0.15
(c) GDM - NMC: 0.33; kNN: 0.27; SVM: 0.42 (d) GIM - NMC: 0.32; kNN: 0.26; SVM: 0.47
Figure 6.3: Results of cross-validation (CV) across the transformated data.
Cross validation was done using three classifiers: Nearest Mean Classifier (NMC), k-Nearest Neighbour (kNN)
and Support Vector Machine (SVM). The values presented are the mean of the classifier’s error rate. The value
of each point are listed in Apprendix-B. The black area is the probability density of the data at different values.
The three red lines are the lower quartile, median and upper quartile. Jaccard transformation is the one which
presents the best results.
The best classifier in Hamming transformation is SVM (0.24) and the worst is NMC. In
SVM, more than 50% values are below 0.2.
The Jaccard transformation has really good results. All classifiers have an average error
rate under 0.2. More than one-third of the values in SVM are under 0.1.
The best classifier in GDM and GIM is kNN (0.27 and 0.26, respectively). On the other
hand, SVM shows to have the worse performance (0.42 and 0.47, respectively)
In general, classifiers have positive results over all transformations. It should be noted
that SVM, in GDM and GIM transformation, has the worst results. Once GIM is a redefined
way of Hamming distance, it was expected that SVM had similar performance as in NMC
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and kNN. It is important to focus that Jaccard has the best performance, where the highest
average error rate is 0.18. This high performance may be justified because, the Jaccard
distance [70], only takes into account if genes have an insertion at least in one sample,
ignoring the genes that does not have insertions in its vicinity.
Due the high dimension and complexity of the dataset, as well as, a gene can be active
in several tumour types and not only a specific one, if a classifier has an error performance
of 0.3 it may be an acceptable value.
6.3. RANKING GENES
Even if the unsupervised learning methods do not show a great visualization, supervised
learning methods shows positive resuts. It means that the data has some relevant feature
being able to distinguish differente tumour types. For that reason, it is possible to rank the
genes according to their importance in a specific tumour type.
Table 6.1 shows the top 15 genes that have more insertions in its vicinity of a specific
tumour type. The name of the respecitive genes are in Appendix C.
Table 6.1: List of the 15 genes more involved in a specific tumour type.
The list contains 103 genes and two of them repeat twice (Fuca1 and Ift46).
Colorectal Hematopoietic
Hepatocellular
carcinoma
Lymphoma
Malignant
peripheral
nerve sheat
Medulloblastoma Pancreatic
Armc7 Gm17535 Gm10337 Pik3r5 Cyp2j8 3110070m22Rik 1810049j17Rik
Akap9 Bc003331 Mrpl48 Gfi1 Pcdhga5 Tgif2 Atxn7
Rspo2 Ddx25 Rhbdd3 Myc Pcdhgb2 Bcl9 Tmc1
4933440n22Rik Pate2 4931422a03Rik Csf2 Zfp106 Gm11273 Gm5129
Fdxacb1 Trpm8 Arid4a Flt3 Ryk Naip2 4933406p04Rik
Baz2a Fam179b Rtl1 Fuca1 Hdlbp Prl3c1 Tcte2
Samd4 Thpo Pdcd11 Ascl2 Epor Akr1c20 Rspry1
Prr36 Abhd13 Ift46 Kit Gpr75 Gm26965 Gm10638
Gm10974 Sepp1 Kntc1 Ccr7 Gm10542 Zfp87 Sugct
2310061n02Rik Gm20537 Dnajb4 Il2rb Cmya5 Rft1 Rapgefl1
Slc6a18 1110059e24Rik Ttc4 Ccnd1 Spink11 Hecw1 4931406c07Rik
Tshb Kmt2e Cdkl3 Atp5h Zfp53 Vmn1r200 Cbx5
Alg9 Fuca1 Tmem106a Il3 Lig4 Gtf2h2 Ift46
Matr3 Trove2 Nat10 Snx9 Tbr1 Foxr2 Ccdc138
Plod1 Rag2 Cbx3 Eras Hus1b Ccl25 Xpnpep3
The presented list of genes is a result of the difference between distributions of inser-
tions in a specific class against the rest of the dataset. It selects the genes that have more
insertions in its vicinity and, contrary, the rest of the dataset does not have. This approach
selects the genes that are probable to be involved in a specific tumour type.
The gene list contains 85 genes already known, described in databases and annotated,
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which 2 of them show up twice - Fuca1 seems to have an important role in HSC and lym-
phoma tumours; and Ift46 in HCC and pancreatic tumours. There are also 18 genes that
are not annotated in the mouse genome (8 Riken complementary DNA (cDNA), 9 predicted
genes and 1 cDNA sequence). Most of the listed genes were already mentioned, in the lit-
erature, as a cancer gene.
An analysis of each set of genes was done. First, to find the relationship among genes,
trying to find clusters of molecular functions between them. This process was done using
DAVID Database [115, 116]. A second step was know if any of the genes listed were already
mentioned before in that tumour type.
The colorectal gene set has a principal function of molecular binding and involved in
signalling process. Two genes have already been mentioned as likely to be involved in this
type of cancer - Akap9 [117] and Rspo2 [118].
Genes of Hematopoietic stem cells (HSC) seem to have molecular functions related to
secretion, signal and are mostly located in the membrane. Thop [119] and Rag2 [120, 121]
are genes suggested to affect in HSC tumour.
The Hepatocellular carcinoma (HCC) set is essentially involved in binding process. Four
genes were referred to be involved in this tumour type - Rhbdd3 [122], Rtl1 [123], Nat10
[124] and Kntc [125].
Lymphoma is the tumour type with more samples and does not have any not-annotated
gene. These set of genes are participates in the leukaemia pathways and have molecular
functions of binding and signalling. From the list of 15 genes, 8 were already mentioned in
the literature to be included in Lymphoma’s tumour- Gfi1 [126], Myc [127], Flt3 [128], Kit
[129], Ccr7 [130], Il2rb [131], Ccnd1 [132] and Il3 [133].
On the set of Malignant peripheral nerve sheath tumour (MPNST), no gene was men-
tioned before to be involved in this tumour type. However, these genes are essentially in-
volved in binding.
Medulloblastoma genes participates in binding and transcription regulation processes.
Tgif2 [92] and Foxr2 [89] are genes already mentioned in the literature, acting in the tumour
type.
The set of pancreatic tumour are also involved in binding mechanisms. Two genes have
already been mentioned as likely to be involved in this type of cancer - Sugct [134, 135]).
According to the data used, it is possible to generalise that each set of genes belongs
to that tumour type. However, there are dozens of different types of cancer. It is quite
impossible to assume that those genes are exclusive to a tumour type. But it is possible to
assume that they may act on them.
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More genes may be involved in tumourigenesis, being classified as oncogenes or tu-
mour suppressor genes. Probably they are involved in several types of cancer. To find them,
a multiclass analysis should be performed.
Given that at least 19 genes support the results, by published papers, these results should
interest biologists. They should analyse them as new target genes, analysing both anno-
tated and not-annotated genes.

7
CONCLUSION
7.1. OVERVIEW
The number of new cancer cases and death as a result of this disease is increasing every
year. However, cancer can be prevented having a healthy lifestyle, avoid risky behaviours
and get regular medical care. Do not having these prevention behaviours can create muta-
tions in the genome. Accumulating those mutations a cell can develop the process to lead
to cancer. The data used in this work are a collection of independent studies of IM in mice.
These integrations can increase or decrease the gene expression on its location.
Machine learning has been a popular strategy for medical researchers. Different ap-
proaches can be able to discover and identify patterns in complex datasets. In this work,
different techniques were used. Four dissimilarity approaches, two of them were devel-
oped to take into account the biological meaning of the data. Two unsupervised learning
method and supervised learning were used. Once these approaches validate the structure
of the data, the feature ranking may be performed.
The main results are set list of the 15 genes for each tumour type. Each one contains the
genes that are probable to be more involved in that tumour type. In summary, 103 genes
were listed, where 18 of them are not annotated. After a bibliographic research, at least 19
genes were already mentioned in the literature to act in that tumour type. For that reason,
these sets of genes can, apparently, be involved in the tumourigenesis process.
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7.2. LIMITATIONS
As all scientific work has its limitations, no exceptions in this case were observed. The main
limitations of this work are described below:
• Transformation data - The gene independent method (GIM) should takes into ac-
count the distribution of match0−0 and match1−1, giving more weight to the match1−1.
In fact, this does not happen with the algorithm, creating, therefore, a re-formulation
of the Hamming distance.
• Unsupervised learning - both PCA and t-SNE visualization are unclear. Testing other
unsupervised learning methods could be helpful.
• Supervised learning - SVM, NMC and kNN have good performance when used in
Jaccard transformation. Nonetheless, in the other transformations, these classifiers
have a bit more error rate. It would be interesting to test more models, or even create
a new one more adapted to the structure of the data.
7.3. RECOMMENDATIONS
Although the main goals proposed for this project have been accomplished, some features
could be added to improve the results:
• Increase the window. It is known that integrations can affect genes in long distances
[35]. Increasing the size of windows, the window space will capture more insertions,
having more informative data and avoiding samples to have no insertions in its vicin-
ity;
• Take into account the position of an insertion. In fact, the integration can be in the
vicinity of a gene, or within it having contradictory results. If an insertion is the vicin-
ity of a gene, it will be more active. On the other hand, if an insertion is within the
gene, it will deregulate it. Knowing their integration position will help to distinguish
between oncogenes and tumour suppressor genes;
• Validation of the results in vitro and in vivo. Validating genes that are involved in
tumourigenesis, researchers can use drug therapy to correct abnormal gene activity
and prevent the development of cancer.
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APPENDIX - DATA TRANSFORMATION
A.1. EXAMPLES OF DISTANCE METRICS
Hamming [69] and Jaccard distance [70] were selected to calculate distances between sam-
ples. Some examples of these distances are presented bellow.
S1= {1,1,1,1,1,1,1,1,1,1} H ammi ng : 0
S2= {1,1,1,1,1,1,1,1,1,1} Jaccar d : 0
S1= {0,0,0,0,0,0,0,0,0,0} H ammi ng : 0
S2= {0,0,0,0,0,0,0,0,0,0} Jaccar d : er r or
S1= {1,1,1,1,1,0,0,0,0,0} H ammi ng : 1
S2= {0,0,0,0,0,1,1,1,1,1} Jaccar d : 1
S1= {1,1,1,1,1,1,1,1,1,1} H ammi ng : 0.5
S2= {1,1,1,1,1,0,0,0,0,0} Jaccar d : 0.5
S1= {0,0,0,0,0,0,0,0,0,0} H ammi ng : 0.5
S2= {1,1,1,1,1,0,0,0,0,0} Jaccar d : 1
S1= {1,1,1,0,0,0,0,0,0,0} H ammi ng : 0.4
S2= {1,1,1,0,0,0,1,1,1,1} Jaccar d : 0.57
S1= {1,1,1,1,0,0,0,0,0,0} H ammi ng : 0.2
S2= {1,1,1,1,0,0,0,0,1,1} Jaccar d : 0.33
S1= {1,1,0,0,0,0,0,0,0,0} H ammi ng : 0.2
S2= {0,0,0,0,0,0,0,0,0,0} Jaccar d : 1
S1= {0,0,1,1,1,1,1,1,1,1} H ammi ng : 0.2
S2= {1,1,1,1,1,1,1,1,1,1} Jaccar d : 0.2
(A.1)
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A.2. ENTIRE DATA TRANSFORMATION
The data wer transformed by the Hamming distance, Jaccard distance, gene dependent
method (GDM) and gene independent method (GIM). This transformation creates a dis-
tance matrix between samples. Figure A.1 the heat map of those transformations.
(a) Hamming distance (b) Jaccard distance
(c) gene dependent method (GDM) (d) gene independent method (GIM)
(e) Tumour types.
Figure A.1: Heat map of the distance matrices generated by the Hamming distance, Jaccard distance, gene
dependent method (GDM) and gene independent method (GIM). Subfigure e shows the position of each
tumour type.
B
APPENDIX - CROSS-VALIDATION VALUES
The values of Figure 6.3 are described in the following four tables:
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Table B.1: Cross-validation using the Hamming transformation.
It was calculated the cross-validation, between two samples, using three classifiers: nearest mean classifier;
k-nearest neighbour; and support vector machine.
Nearest Mean classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.1575 0.4236 0.2752 0.4555 0.4554 0.3492
HSC 0.1575 - 0.2227 0.3861 0.1479 0.1244 0.1001
HCC 0.4236 0.2227 - 0.2975 0.4279 0.4394 0.5028
Lymphoma 0.2752 0.3861 0.2975 - 0.2464 0.2380 0.1876
MPNST 0.4555 0.1479 0.4279 0.2464 - 0.4884 0.3837
Medulloblastoma 0.4554 0.1244 0.4394 0.2380 0.4884 - 0.3789
Pancreatic 0.3492 0.1001 0.5028 0.1876 0.3837 0.3789 -
k-Nearest Neighbour classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.1675 0.1612 0.2732 0.4559 0.4429 0.3721
HSC 0.1675 - 0.1907 0.3502 0.1501 0.1381 0.1076
HCC 0.1612 0.1907 - 0.1854 0.1642 0.1441 0.2492
Lymphoma 0.2732 0.3502 0.1854 - 0.2607 0.2398 0.2139
MPNST 0.4559 0.1501 0.1642 0.2607 - 0.4976 0.3861
Medulloblastoma 0.4429 0.1381 0.1441 0.2398 0.4976 - 0.3161
Pancreatic 0.3721 0.1076 0.2492 0.2139 0.3861 0.3161 -
Suport Vector Machine classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.1342 0.4205 0.2564 0.2602 0.3055 0.3307
HSC 0.1342 - 0.1761 0.2557 0.1479 0.1246 0.1001
HCC 0.4205 0.1761 - 0.2733 0.1770 0.1481 0.1942
Lymphoma 0.2564 0.2557 0.2733 - 0.1304 0.1376 0.1297
MPNST 0.2602 0.1479 0.1770 0.1304 - 0.4832 0.3812
Medulloblastoma 0.3055 0.1246 0.1481 0.1376 0.4832 - 0.3741
Pancreatic 0.3307 0.1001 0.1942 0.1297 0.3812 0.3741 -
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Table B.2: Cross-validation using the Jaccard transformation.
It was calculated the cross-validation, between two samples, using three classifiers: nearest mean classifier;
k-nearest neighbour; and support vector machine.
Nearest Mean classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.1683 0.1453 0.1300 0.1808 0.2456 0.2353
HSC 0.1683 - 0.0925 0.2368 0.2131 0.1748 0.0918
HCC 0.1453 0.0925 - 0.0681 0.1560 0.1335 0.1975
Lymphoma 0.1300 0.2368 0.0681 - 0.0895 0.1148 0.0698
MPNST 0.1808 0.2131 0.1560 0.0895 - 0.2767 0.1639
Medulloblastoma 0.2456 0.1748 0.1335 0.1148 0.2767 - 0.1682
Pancreatic 0.2353 0.0918 0.1975 0.0698 0.1639 0.1682 -
k-Nearest Neighbour classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.1958 0.0939 0.1384 0.2934 0.2630 0.3494
HSC 0.1958 - 0.2163 0.2556 0.1319 0.1149 0.1007
HCC 0.0939 0.2163 - 0.0913 0.1240 0.0748 0.1708
Lymphoma 0.1384 0.2556 0.0913 - 0.1168 0.1164 0.1162
MPNST 0.2934 0.1319 0.1240 0.1168 - 0.3057 0.2476
Medulloblastoma 0.2630 0.1149 0.0748 0.1164 0.3057 - 0.2630
Pancreatic 0.3494 0.1007 0.1708 0.1162 0.2476 0.2630 -
Suport Vector Machine classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.1886 0.0972 0.1296 0.1892 0.2484 0.2461
HSC 0.1886 - 0.0713 0.2606 0.1779 0.1608 0.0767
HCC 0.0972 0.0713 - 0.0506 0.0955 0.0895 0.1312
Lymphoma 0.1296 0.2606 0.0506 - 0.0880 0.1075 0.0683
MPNST 0.1892 0.1779 0.0955 0.0880 - 0.2706 0.1675
Medulloblastoma 0.2484 0.1608 0.0895 0.1075 0.2706 - 0.1752
Pancreatic 0.2461 0.0767 0.1312 0.0683 0.1675 0.1752 -
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Table B.3: Cross-validation using the GDM transformation.
It was calculated the cross-validation, between two samples, using three classifiers: nearest mean classifier;
k-nearest neighbour; and support vector machine.
Nearest Mean classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.1493 0.3940 0.3670 0.4595 0.5119 0.3618
HSC 0.1493 - 0.1955 0.2731 0.1400 0.1326 0.1069
HCC 0.3940 0.1955 - 0.3314 0.4005 0.3956 0.4547
Lymphoma 0.3670 0.2731 0.3314 - 0.3482 0.3686 0.2759
MPNST 0.4595 0.1400 0.4005 0.3482 - 0.4588 0.4030
Medulloblastoma 0.5119 0.1326 0.3956 0.3686 0.4588 - 0.3569
Pancreatic 0.3618 0.1069 0.4547 0.2759 0.4030 0.3569 -
k-Nearest Neighbour classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.1828 0.1771 0.3574 0.4473 0.4636 0.3749
HSC 0.1828 - 0.1915 0.3161 0.1534 0.1496 0.1169
HCC 0.1771 0.1915 - 0.1519 0.1641 0.1338 0.2182
Lymphoma 0.3574 0.3161 0.1519 - 0.2576 0.3306 0.2254
MPNST 0.4473 0.1534 0.1641 0.2576 - 0.4900 0.4273
Medulloblastoma 0.4636 0.1496 0.1338 0.3306 0.4900 - 0.3718
Pancreatic 0.3749 0.1169 0.2182 0.2254 0.4273 0.3718 -
Suport Vector Machine classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.3700 0.3864 0.4011 0.5086 0.5373 0.4463
HSC 0.3700 - 0.4098 0.4310 0.4127 0.3922 0.4261
HCC 0.3864 0.4098 - 0.3188 0.4400 0.3448 0.4441
Lymphoma 0.4011 0.4310 0.3188 - 0.3998 0.3986 0.4026
MPNST 0.5086 0.4127 0.4400 0.3998 - 0.4682 0.5356
Medulloblastoma 0.5373 0.3922 0.3448 0.3986 0.4682 - 0.4196
Pancreatic 0.4463 0.4261 0.4441 0.4026 0.5356 0.4196 -
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Table B.4: Cross-validation using the GIM transformation.
It was calculated the cross-validation, between two samples, using three classifiers: nearest mean classifier;
k-nearest neighbour; and support vector machine.
Nearest Mean classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.1526 0.4230 0.2748 0.4487 0.4545 0.3510
HSC 0.1526 - 0.2234 0.3843 0.1462 0.1251 0.0935
HCC 0.4230 0.2234 - 0.2974 0.4299 0.4418 0.5033
Lymphoma 0.2748 0.3843 0.2974 - 0.2483 0.2387 0.1900
MPNST 0.4487 0.1462 0.4299 0.2483 - 0.4903 0.3910
Medulloblastoma 0.4545 0.1251 0.4418 0.2387 0.4903 - 0.3753
Pancreatic 0.3510 0.0935 0.5033 0.1900 0.3910 0.3753 -
k-Nearest Neighbour classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.1607 0.1598 0.2697 0.4510 0.4492 0.3538
HSC 0.1607 - 0.1836 0.3513 0.1476 0.1389 0.1258
HCC 0.1598 0.1836 - 0.2032 0.1583 0.1461 0.2530
Lymphoma 0.2697 0.3513 0.2032 - 0.2592 0.2472 0.2059
MPNST 0.4510 0.1476 0.1583 0.2592 - 0.4705 0.3728
Medulloblastoma 0.4492 0.1389 0.1461 0.2472 0.4705 - 0.3458
Pancreatic 0.3538 0.1258 0.2530 0.2059 0.3728 0.3458 -
Suport Vector Machine classification
Colorectal HSC HCC Lymphoma MPNST Medulloblastoma Pancreatic
Colorectal - 0.4433 0.4106 0.4941 0.5008 0.5005 0.4932
HSC 0.4433 - 0.4174 0.4475 0.4348 0.5973 0.3949
HCC 0.4106 0.4174 - 0.4383 0.3748 0.6201 0.3651
Lymphoma 0.4941 0.4475 0.4383 - 0.4858 0.4750 0.5040
MPNST 0.5008 0.4348 0.3748 0.4858 - 0.4782 0.4776
Medulloblastoma 0.5005 0.5973 0.6201 0.4750 0.4782 - 0.4997
Pancreatic 0.4932 0.3949 0.3651 0.5040 0.4776 0.4997 -
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APPENDIX - GENE LIST
The list of predicted genes involved in a specific tumour type are described bellow:
1110059e24Rik RIKEN cDNA 1110059E24 gene; predicted gene 9504
1810049j17Rik RIKEN cDNA 1810049J17 gene
2310061n02Rik RIKEN cDNA 2310061N02 gene
3110070m22Rik RIKEN cDNA 3110070M22 gene
4931406c07Rik RIKEN cDNA 4931406C07 gene
4931422a03Rik RIKEN cDNA 4931422A03 gene
4933406p04Rik RIKEN cDNA 4933406P04 gene
4933440n22Rik RIKEN cDNA 4933440N22 gene
Abhd13 abhydrolase domain containing 13
Akap9 A-kinase anchor protein 9
Akr1c20 aldo-keto reductase family 1, member C20
Alg9 asparagine-linked glycosylation 9 homolog (yeast, alpha 1,2 mannosyltransferase)
Arid4a AT rich interactive domain 4A (RBP1-like)
Armc7 armadillo repeat containing 7
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Ascl2 achaete-scute family bHLH transcription factor 2
Atp5h ATP synthase, H+ transporting, mitochondrial Fo complex, subunit d
Atxn7 ataxin 7
Baz2a bromodomain adjacent to zinc finger domain, 2A
Bc003331 cDNA sequence BC003331
Bcl9 B-cell CLL/lymphoma 9
Cbx3 chromobox homolog 3
Cbx5 ataxin 7
Ccdc138 coiled-coil domain containing 138
Ccl25 C-C motif chemokine 25
Ccnd1 cyclin D1
Ccr7 chemokine (C-C motif) receptor 7
Cdkl3 cyclin-dependent kinase-like 3
Cmya5 cardiomyopathy associated 5
Csf2 colony stimulating factor 2
Cyp2j8 cytochrome P450, family 2, subfamily j, polypeptide 8
Ddx25 DEAD (Asp-Glu-Ala-Asp) box polypeptide 25
Dnajb4 DnaJ (Hsp40) homolog, subfamily B, member 4
Epor erythropoietin receptor
Eras ES cell-expressed Ras
Fam179b Family with sequence similarity 179, member B
Fdxacb1 ferredoxin-fold anticodon binding domain containing 1
Flt3 fms-related tyrosine kinase 3
Foxr2 forkhead box R2
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Fuca1 fucosidase, alpha-L- 1, tissue
Gfi1 growth factor independent 1 transcription repressor
Gm10337 predicted gene 10337
Gm10537 predicted gene 10537
Gm10542 predicted gene 10542
Gm10638 predicted gene 10638
Gm10974 predicted gene 10974
Gm11273 predicted gene 11273
Gm17535 predicted gene 17535
Gm26965 predicted gene 26965
Gm5129 predicted gene 5129
Gpr75 G protein-coupled receptor 75
Gtf2h2 general transcription factor II H, polypeptide 2
Hdlbp high density lipoprotein (HDL) binding protein
Hecw1 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1
Hus1b Hus1 homolog b (S. pombe)
Ift46 intraflagellar transport 46
Il2rb interleukin 2 receptor, beta
Il3 interleukin 3
Kit kit oncogene
Kmt2e lysine (K)-specific methyltransferase 2E
Kntc1 kinetochore associated 1
Lig4 ligase IV, DNA, ATP-dependent
Matr3 matrin 3; similar to Matrin 3
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Mrpl48 mitochondrial ribosomal protein L48
Myc myelocytomatosis oncogene
Naip2 NLR family, apoptosis inhibitory protein 2
Nat10 N-acetyltransferase 10
Pate2 prostate and testis expressed 2
Pcdhga5 protocadherin gamma subfamily A, 5
Pcdhgb2 protocadherin gamma subfamily B, 2
Pdcd11 programmed cell death 11
Pik3r5 phosphoinositide-3-kinase, regulatory subunit 5
Plod1 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1
Prl3c1 prolactin family 3, subfamily c, member 1
Prr36 proline rich 36
Rag2 recombination activating gene 2
Rapgefl1 Rap guanine nucleotide exchange factor (GEF)-like 1
Rft1 RFT1 homolog (S. cerevisiae)
Rhbdd3 rhomboid domain containing 3
Rspo2 R-spondin 2 homolog (Xenopus laevis)
Rspry1 ring finger and SPRY domain containing 1
Rtl1 retrotransposon-like 1; RIKEN cDNA 6430411K18 gene
Ryk receptor-like tyrosine kinase
Samd4 sterile alpha motif domain containing 4
Sepp1 selenoprotein P, plasma, 1
Slc6a18 solute carrier family 6 (neurotransmitter transporter), member 18
Snx9 sorting nexin 9
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Spink11 serine peptidase inhibitor, Kazal type 11
Sugct succinyl-CoA:glutarate-CoA transferase
Tbr1 T-box brain gene 1
Tcte2 t-complex-associated testis expressed 2
Tgif2 TGFB-induced factor homeobox 2
Thpo thrombopoietin
Tmc1 transmembrane channel-like gene family 1
Tmem106a transmembrane protein 106A
Trove2 TROVE domain family, member 2
Trpm8 transient receptor potential cation channel, subfamily M, member 8
Tshb thyroid stimulating hormone, beta subunit
Ttc4 tetratricopeptide repeat domain 41
Vmn1r200 vomeronasal 1 receptor, H3
Xpnpep3 X-prolyl aminopeptidase (aminopeptidase P) 3, putative
Zfp106 zinc finger protein 106
Zfp53 zinc finger protein 53
Zfp87 zinc finger protein 87
